Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Alaa A. Makki, Walaa Ibraheem & Abdulrahim A. Alzain. (2023) Cytosporone E analogues as BRD4 inhibitors for cancer treatment: molecular docking and molecular dynamic investigations. Journal of Biomolecular Structure and Dynamics 41:22, pages 12643-12653.
Read now
Read now
Articles from other publishers (36)
Yuhei Horai, Naoki Suda, Shinsuke Uchihashi, Mayako Katakuse, Tomomi Shigeno, Takashige Hirano, Junichi Takahara, Tomoyuki Fujita, Yohei Mukoyama & Yuji Haga. (2023) Discovery of a potent, orally available tricyclic derivative as a novel BRD4 inhibitor for melanoma. Bioorganic & Medicinal Chemistry 93, pages 117461.
Crossref
Crossref
Mahmoud A. A. Ibrahim, Mahmoud M. H. Abdelhamid, Khlood A. A. Abdeljawaad, Alaa H. M. Abdelrahman, Gamal A. H. Mekhemer, Peter A. Sidhom, Shaban R. M. Sayed, Paul W. Paré, Mohamed-Elamir F. Hegazy & Tamer Shoeib. (2023) Pyronaridine as a Bromodomain-Containing Protein 4-N-Terminal Bromodomain (BRD4-BD1) Inhibitor: In Silico Database Mining, Molecular Docking, and Molecular Dynamics Simulation. Molecules 28:15, pages 5713.
Crossref
Crossref
Xing-Jie Dai, Lei-Peng Xue, Shi-Kun Ji, Ying Zhou, Ya Gao, Yi-Chao Zheng, Hui-Min Liu & Hong-Min Liu. (2023) Triazole-fused pyrimidines in target-based anticancer drug discovery. European Journal of Medicinal Chemistry 249, pages 115101.
Crossref
Crossref
Xiaoyang Yu, Quanxin Long, Sheng Shen, Zhentao Liu, Jithin Chandran, Junjie Zhang, Hao Ding, Hu Zhang, Dawei Cai, Elena S. Kim, Yufei Huang & Haitao Guo. (2023) Screening of an epigenetic compound library identifies BRD4 as a potential antiviral target for hepatitis B virus covalently closed circular DNA transcription. Antiviral Research 211, pages 105552.
Crossref
Crossref
Jian-Bo Tong, Xue-Chun Xiao, Ding Luo, Hai-Yin Xu, Yi-Chuang Xing, Peng Gao & Yuan Liu. (2023) Discovery of novel BRD4-BD2 inhibitors via in silico approaches: QSAR techniques, molecular docking, and molecular dynamics simulations. Molecular Diversity.
Crossref
Crossref
Yan-Ling Chen, Xiao-Lu Li, Gen Li, Yan-Fang Tao, Ran Zhuo, Hai-Bo Cao, Wan-yan Jiao, Zhi-Heng Li, Zhen-Hong Zhu, Fang Fang, Yi Xie, Xin-Mei Liao, Di Wu, Hai-Rong Wang, Juan-Juan Yu, Si-Qi Jia, Yang Yang, Chen-Xi Feng, Peng-Cheng Yang, Xiao-Dong Fei, Jian-Wei Wang, Yun-Yun Xu, Guang-Hui Qian, Zi-Mu Zhang & Jian Pan. (2022) BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma. Cell & Bioscience 12:1.
Crossref
Crossref
Liya Ma, Gen Li, Tianquan Yang, Li Zhang, Xinxin Wang, Xiaowen Xu & Hong Ni. (2022) An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16. Cancer Chemotherapy and Pharmacology 90:6, pages 431-444.
Crossref
Crossref
Yang Shi, Meiqi Wang, Dan Liu, Saif Ullah, Xing Ma, Huiyu Yang & Bingrong Liu. (2022) Super-enhancers in esophageal carcinoma: Transcriptional addictions and therapeutic strategies. Frontiers in Oncology 12.
Crossref
Crossref
Wang-Jing Zhong, Lingdi Ma, Fanfan Yang, Jialin Cao, Junyu Tan & Bohong Li. (2022) Matrine, a potential c-Myc inhibitor, suppresses ribosome biogenesis and nucleotide metabolism in myeloid leukemia. Frontiers in Pharmacology 13.
Crossref
Crossref
Jing-jing Zhuang, Qian Liu, Da-lei Wu & Lu Tie. (2022) Current strategies and progress for targeting the “undruggable” transcription factors. Acta Pharmacologica Sinica 43:10, pages 2474-2481.
Crossref
Crossref
Xiao-Li Zhou, Fang Zhao, Yong-Tao Xu, Yuan-Yuan Guan, Tong Yu, Yi-Zhe Zhang, Ying-Chao Duan & Yuan Zhao. (2022) A Comprehensive Review of BET-targeting PROTACs for Cancer Therapy. Bioorganic & Medicinal Chemistry, pages 117033.
Crossref
Crossref
Margarita E. Neganova, Sergey G. Klochkov, Yulia R. Aleksandrova & Gjumrakch Aliev. (2022) Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Seminars in Cancer Biology 83, pages 452-471.
Crossref
Crossref
Qiong Xiao, Yong Xiao, Lian-Yun Li, Ming-Kai Chen & Min Wu. (2022) Multifaceted regulation of enhancers in cancer. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1865:6, pages 194839.
Crossref
Crossref
Ritesh K. Srivastava, Purushotham Guroji, Lin Jin, M. Shahid Mukhtar & Mohammad Athar. (2022) Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism. Molecular Carcinogenesis 61:8, pages 737-751.
Crossref
Crossref
Zeru Li, Bangbo Zhao, Cheng Qin, Yuanyang Wang, Tianhao Li & Weibin Wang. (2022) Chromatin Dynamics in Digestive System Cancer: Commander and Regulator. Frontiers in Oncology 12.
Crossref
Crossref
Mandakini B. Singh, Christopher J. Babigian & Gregory C. Sartor. (2022) Domain-selective BET inhibition attenuates transcriptional and behavioral responses to cocaine. Neuropharmacology 210, pages 109040.
Crossref
Crossref
Soumia Maach, Niccolò Chiaramonte, Vittoria Borgonetti, Federica Sarno, Federica Pierucci, Silvia Dei, Elisabetta Teodori, Lucia Altucci, Elisabetta Meacci, Nicoletta Galeotti & Maria Novella Romanelli. (2022) Dual HDAC–BRD4 inhibitors endowed with antitumor and antihyperalgesic activity. Medicinal Chemistry Research 31:6, pages 960-974.
Crossref
Crossref
Rogy R. Ezz Eldin, Ahmed A. Al-Karmalawy, Mohammad Hayal Alotaibi & Marwa A. Saleh. (2022) Quinoxaline derivatives as a promising scaffold for breast cancer treatment. New Journal of Chemistry 46:21, pages 9975-9984.
Crossref
Crossref
Aishwarya H. Arole, Prashant Deshmukh, Ashok Sridhar & Balasundaram Padmanabhan. (2022) Structural investigation of a pyrano-1,3-oxazine derivative and the phenanthridinone core moiety against BRD2 bromodomains. Acta Crystallographica Section F Structural Biology Communications 78:3, pages 119-127.
Crossref
Crossref
Mingsong Shi, Jun He, Tiantian Weng, Na Shi, Wenyan Qi, Yong Guo, Tao Chen, Lijuan Chen & Dingguo Xu. (2022) The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation. Physical Chemistry Chemical Physics 24:8, pages 5125-5137.
Crossref
Crossref
Sakamuri Sarath Babu, A Anagha Varma & Purushothaman Gopinath. (2022)
Photoredox catalyzed cascade CF
3
addition/chemodivergent annulations of
ortho
-alkenyl aryl ureas
. Chemical Communications 58:12, pages 1990-1993.
Crossref
Crossref
Wenke Jin, Huidan Tan, Junhao Wu, Gu He & Bo Liu. (2022) Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions. Drug Discovery Today 27:1, pages 246-256.
Crossref
Crossref
Enming Xing, Nandini Surendranathan, Xiaotian Kong, Natalie Cyberski, Jessica D. Garcia, Xiaolin Cheng, Amit Sharma, Pui-Kai Li & Ross C. Larue. (2021) Development of Murine Leukemia Virus Integrase-Derived Peptides That Bind Brd4 Extra-Terminal Domain as Candidates for Suppression of Acute Myeloid Leukemia. ACS Pharmacology & Translational Science 4:5, pages 1628-1638.
Crossref
Crossref
Negar Omidkhah, Farzin Hadizadeh & Razieh Ghodsi. (2021) Dual HDAC/BRD4 inhibitors against cancer. Medicinal Chemistry Research 30:10, pages 1822-1836.
Crossref
Crossref
Hang Zhang, Mingliang Zhang, Yi-Chao Zheng, Jin-Ge Zhang & Haiwei Xu. (2021) The design, synthesis and cellular imaging of a tumor-anchored, potent and cell-permeable BRD4-targeted fluorescent ligands. Bioorganic Chemistry 114, pages 105120.
Crossref
Crossref
Jian-Bo Tong, Ding Luo, Yi Feng, Shuai Bian, Xing Zhang & Tian-Hao Wang. (2021) Structural modification of 4, 5-dihydro-[1, 2, 4] triazolo [4, 3-f] pteridine derivatives as BRD4 inhibitors using 2D/3D-QSAR and molecular docking analysis. Molecular Diversity 25:3, pages 1855-1872.
Crossref
Crossref
Ellen E. Guest, Stephen D. Pickett & Jonathan D. Hirst. (2021) Structural variation of protein–ligand complexes of the first bromodomain of BRD4. Organic & Biomolecular Chemistry 19:25, pages 5632-5641.
Crossref
Crossref
Harish Iyer, Abhipradnya B. Wahul, Annapoorna P. K., Bharvi S. Sawant & Arvind Kumar. (2021) A BRD’s (BiRD’s) eye view of BET and BRPF bromodomains in neurological diseases. Reviews in the Neurosciences 32:4, pages 403-426.
Crossref
Crossref
Hua Yang, Li Wei, Yang Xun, Anping Yang & Hua You. (2021) BRD4: An emerging prospective therapeutic target in glioma. Molecular Therapy - Oncolytics 21, pages 1-14.
Crossref
Crossref
Kristine E. Yoder, Anthony J. Rabe, Richard Fishel & Ross C. Larue. (2021) Strategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Lara Paracchini, Luca Beltrame, Tommaso Grassi, Alessia Inglesi, Robert Fruscio, Fabio Landoni, Davide Ippolito, Martina Delle Marchette, Mariachiara Paderno, Marco Adorni, Marta Jaconi, Chiara Romualdi, Maurizio D'Incalci, Giulia Siravegna & Sergio Marchini. (2021) Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer. Clinical Cancer Research 27:9, pages 2549-2559.
Crossref
Crossref
Francesca Megiorni, Simona Camero, Paola Pontecorvi, Lucrezia Camicia, Francesco Marampon, Simona Ceccarelli, Eleni Anastasiadou, Nicola Bernabò, Giorgia Perniola, Antonio Pizzuti, Pierluigi Benedetti Panici, Vincenzo Tombolini & Cinzia Marchese. (2021) OTX015 Epi-Drug Exerts Antitumor Effects in Ovarian Cancer Cells by Blocking GNL3-Mediated Radioresistance Mechanisms: Cellular, Molecular and Computational Evidence. Cancers 13:7, pages 1519.
Crossref
Crossref
Julie Ross, Caitlin E. Miron, Jessica Plescia, Patricia Laplante, Kevin McBride, Nicolas Moitessier & Tarik Möröy. (2021) Targeting MYC: From understanding its biology to drug discovery. European Journal of Medicinal Chemistry 213, pages 113137.
Crossref
Crossref
Jinhui Cui, Xinjuan Chen, Shuo Lin, Ling Li, Jianhui Fan, Hongying Hou & Ping Li. (2020) MiR-101-containing extracellular vesicles bind to BRD4 and enhance proliferation and migration of trophoblasts in preeclampsia. Stem Cell Research & Therapy 11:1.
Crossref
Crossref
Rong Deng, Jun-Hao Huang, Yan Wang, Li-Huan Zhou, Zi-Feng Wang, Bing-Xin Hu, Yu-Hong Chen, Dong Yang, Jia Mai, Zhi-Ling Li, Hai-Liang Zhang, Yun Huang, Xiao-Dan Peng, Gong-Kan Feng, Xiao-Feng Zhu & Jun Tang. (2020) Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma. Molecular Cancer 19:1.
Crossref
Crossref
Patricia Cristine BorckLian-Wang GuoJorge Plutzky. (2020) BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs. Circulation Research 126:9, pages 1190-1208.
Crossref
Crossref